CDMOs, collateral victims of disaffection for the Covid-19 vaccine?

2023-12-01 07:55:00

What remains of the unprecedented production effort launched during the Covid-19 pandemic? In 2021, CDMOs benefited from an unprecedented spotlight during the health crisis, with the production of the mRNA vaccine. Two years later, the record volumes requested to cope with the massive vaccination campaigns fizzled out. And push subcontractors to adapt.

Latest to date, Recipharm announced the cessation of its activities at its Monts site, in Indre-et-Loire, from the second quarter of 2025. Belonging to the Swedish group since 2007, the site employs 225 people and specializes in THE fill & finishi.e. filling operations, in aseptic conditions.


This article is reserved for our Industrie Pharma and Usine Nouvelle subscribers

Support expert journalism.

Already subscribed?
Log in

Selected for you

#CDMOs #collateral #victims #disaffection #Covid19 #vaccine

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.